[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

TAKEDA, Vortioxetine (Brintellix) – US Approval for MDD Likely in October – Competitive Enough Against Genericized MDD Market, Yet Maturing Late Stage Pipeline Candidates Warrant A Close Watch!

August 2013 | 4 pages | ID: TEC4FFF72D5EN
MP Advisors

US$ 140.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Takeda’s late stage pipeline candidate – Vortioxetine (Filed, Partnered with Lundbeck, US PDUFA on October 2nd) is expected to get FDA approval for the treatment of Major Depressive Disorder (MDD). Despite the fact that antidepressant market will be ~fully genericized by 2013 (when Cymbalta will go off patent in Dec 2013), there are ~dozen of compounds in mid-late stage development for the treatment of MDD (Table-1). Increasing prevalence, high unmet need (poor tolerability, moderate efficacy, and thus switching as an unavoidable phenomenon among existing options), and treatment resistance create the need for newer options and still present an attractive market for new entrants. Reported PhIII data of Vortioxetine look. However, other pipeline candidates are chasing Vortioxetine very closely.


More Publications